Heart attack patients get early cholesterol drug in landmark trial
NCT ID NCT07290699
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether giving a powerful cholesterol-lowering drug (recaticimab) early after a heart attack can safely reduce future heart problems. About 2,442 adults who recently had a heart attack will receive the drug or standard care. The goal is to see if this approach lowers cholesterol, controls inflammation, and prevents major heart events like another heart attack or stroke.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STEMI - ST ELEVATION MYOCARDIAL INFARCTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••